Mefküre Durmuş

Dr. Mefküre Durmuş

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
SGSelim Gök
Selim Gök
ÖBÖmer Faruk Bahçecioğlu
Ömer Faruk Bahçecioğlu
MDMefküre Durmuş
Mefküre Durmuş
ZGZeynep Ülkü Gün
Zeynep Ülkü Gün
YEYasemin Ersoy
Yasemin Ersoy
ÖUÖzkan Ulutaş
Özkan Ulutaş
Objective The safety profile of favipiravir in patients with severe renal impairment has not been investigated and available data are insufficient. The study aimed to compare the incidence of favipiravir-associated adverse events amongst patients with varying renal function statuses. Methods Records of 921 patients who were hospitalised for COVID-19 and had received at least 5 days of favipiravir treatment were retrospectively evaluated and 228 patients were included in the study. Patients' age, sex, comorbidities, estimated glomerular filtration rate (eGFR) and haematological and biochemical values were recorded. The incidence of adverse events was compared with the age, sex, comorbidities and eGFR of the patients. Results The mean age of the patients was 59.3 +/- 15.6 years, and 38.2% of the patients were women. One hundred and thirty-one (57.5%) patients had experienced adverse events. These adverse effects consisted of ALT elevation (35.5%), AST elevation (21.5%), anaemia (16.2%), hyperuricaemia (10.5%), hepatocellular injury (9.2%), neutropenia (3.5%) and thrombocytopenia (2.6%). The incidence of adverse events was not significantly different when patients had eGFR >60 mL/min/1.73 m(2) or eGFR 30-60 mL/min/1.73 m(2) (P > .05), but significantly increased when the eGFR dropped to <30 (P < .05). The differences seen with hyperuricaemia and anaemia were significant (P < .05). Conclusion Even though favipiravir appeared to be well tolerated in the individuals with renal failure in this study, its use in this population remains a challenge that requires more research and analysis.

1 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MDMefküre Durmuş
Mefküre Durmuş
SKsena güzel karahan
sena güzel karahan
Sami AkbulutSami Akbulut
Sami Akbulut
ZYZeynep Burcin Yilmaz
Zeynep Burcin Yilmaz
EKErtugrul Karabulut
Ertugrul Karabulut
Background: Liver transplant recipients are highly susceptible to invasive fungal infections, particularly candidemia, due to intensive immunosuppressive therapy and postoperative complications. However, few studies have comprehensively examined postoperative antimicrobial and immunosuppressive factors in this context. Aim: This study aimed to identify perioperative and postoperative factors associated with the development of candidemia in living donor liver transplant (LDLT) recipients, with a particular focus on antimicrobial and immunosuppressive regimens during initial hospitalization. Methods: A retrospective case–control analysis was conducted involving 36 LDLT recipients who developed candidemia (candidemia group) and 72 matched controls without candidemia (non-candidemia group) between January 2019 and November 2023. Demographic and clinical variables were compared using univariate and multivariate logistic regression analyses to identify independent associations. A post hoc power analysis demonstrated a high statistical power (97.3%) to detect large effect sizes. Results: Univariate analysis revealed significant associations with prolonged intubation (p < 0.001), bile leaks (p < 0.001), relaparotomy (p < 0.001), chronic renal disease (p = 0.011), hepatocellular carcinoma (p = 0.011), and the use of antimicrobials including meropenem (p = 0.048), linezolid (p = 0.005), tigecycline (p = 0.045), third-generation cephalosporins (p = 0.003), anidulafungin (p < 0.001), fluconazole (p = 0.006), mycophenolate (p = 0.011), and total parenteral nutrition (TPN) (p = 0.049). CMV prophylaxis (p < 0.001) and CMV-PCR positivity (p = 0.015) were also significantly associated with candidemia. Multivariate logistic regression analysis identified prolonged intubation (OR = 1.07; p = 0.019), bile leaks (OR = 10.9; p = 0.002), anidulafungin use (OR = 4.70; p = 0.032), fluconazole use (OR = 35.8; p = 0.005), and absence of CMV prophylaxis (OR = 11.7; p = 0.021) as independent factors associated with increased odds of candidemia. Conclusions: Prolonged intubation, bile leaks, antifungal exposure, and lack of CMV prophylaxis are independently associated with higher odds of candidemia after LDLT. Targeted prophylaxis, prudent antimicrobial stewardship, and timely biliary intervention may reduce fungal morbidity and mortality in post-transplant patients.

1 September 2026 in Endocrinology Research and Practice
Verified
Journal Article
Open access
PDF file
SUSena Ustaömer
Sena Ustaömer
MDMefküre Durmuş
Mefküre Durmuş
ÖÜÖzge Üçüncü
Özge Üçüncü
MKMustafa KOCAK
Mustafa KOCAK
Objective: Hypothyroidism requires lifelong levothyroxine (LT4) therapy, yet achieving target thyroid-stimulating hormone (TSH) levels is often hindered by complex drug–food interactions and poor adherence. This study evaluated the impact of clinical pharmacist-led education on LT4 adherence and treatment effectiveness. Methods: This uncontrolled pre–post interventional study was conducted between November 2024 and April 2025 in an endocrinology outpatient clinic. Patients diagnosed with hypothyroidism initiating LT4 therapy were included. Baseline sociodemographic data and medication habits were recorded, and adherence was assessed using the Turkish-validated Medication Adherence Report Scale-5 (MARS-5). Participants received a 10-min structured verbal education session and an informative brochure. After 3 months, a follow-up was conducted via telephone to re-administer MARS-5 and retrieve serum TSH and free thyroxine (fT4) values from hospital records. Results: Among 152 participants (median age 51; 86.2% female), the median MARS-5 score significantly increased from 24.0 (interquartile range (IQR) 22.0-25.0) to 25.0 (IQR 24.0-25.0; P < .001). Median TSH levels significantly decreased from 2.04 (0.80-3.95) to 1.17 (0.39-3.16) mIU/L (P =.002), while fT4 levels remained stable. Notably, the proportion of patients taking LT4 at least 30 min before breakfast improved from 45.7% to 96.7% (P < .001). Conclusion: A brief, structured clinical pharmacist-led intervention significantly improved LT4 adherence and biochemical treatment outcomes. These findings underscore the clinical value of integrating pharmacist-led education and follow-up services into routine outpatient care to optimize long-term management of hypothyroidism. Cite this article as: Ustaömer S, Durmuş M, Üçüncü Ö, Koçak M. Improving levothyroxine adherence and thyroid-stimulating hormone control via structured clinical pharmacist-led education in patients with hypothyroidism. Endocrinol Res Pract. Published online September 1, 2026. doi: 10.5152/erp.2026.26986.

26 November 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MDMefküre Durmuş
Mefküre Durmuş
DADavut Aydın
Davut Aydın
SUSena Ustaömer
Sena Ustaömer
SKSena Güzel Karahan
Sena Güzel Karahan
AKAhmet Oğuzhan Küçük
Ahmet Oğuzhan Küçük
MKMehtap Pehlivanlar Küçük
Mehtap Pehlivanlar Küçük
Trimethoprim-sulfamethoxazole (TMP-SMX) has been used clinically against many gram-positive and gram-negative bacteria, Pneumocystis, and certain protozoa.

28 April 2019 in Mersin Üniversitesi Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
MDMefküre Durmuş
Mefküre Durmuş
BBBurak Barut
Burak Barut
AÖArzu Özel
Arzu Özel
HSHasan Erdinç SELLİTEPE
Hasan Erdinç SELLİTEPE
İDİnci Selin DOGAN
İnci Selin DOGAN
Aril(alkil)azol grubu bileşikler antifungal, antikonvülsan, antibakteriyel aktivitelere sahiptir. Hem oksijenaz enzim inhibisyonu, indolamin 2,3-dioksigenaz-1 enzim inhibisyonu, asetilkolinesteraz (AChE) ve bütirilkolinesteraz (BChE) enzim inhibisyonu aktivitelerinin değerlendirildiği çalışmalar da mevcuttur. Bu çalışmada, aril (alkil) azol yapısında, 2(1H-1,2,4-triazol-1-il)-1-(2,4-diklorofenil) etanol bileşiği ve bu bileşikten hareketle üç adet yeni aromatik yan zincir içeren ester türevleri sentezlendi. Başka bir çalışmada sentezlenen yapısında triazol yerine izosteri olan imidazol halkası taşıyan, dört adet bileşik ve bu çalışmada sentezlenen bileşiklerin AChE ve BChE enzim inhibisyonu Ellman metodunun modifiye şekli ile değerlendirilirken, antioksidan aktivitesi 1,1-difenil-2-pikrilhidrazil (DPPH) radikal süpürücü aktivite yöntemi ile değerlendirildi. Sentezlenen yeni bileşiklerin yapıları IR, 1H-NMR, 13C-NMR ve LC-MS spektroskopik yöntemlerle kanıtlandı. 1, 2, 4-Triazol türevlerinde herhangi bir aktivite görülmezken, imidazol türevi bileşiklerde AChE enzim inhibisyonu ve DPPH radikal süpürücü aktivite gözlenmiştir. İmidazol türevlerinde enzim inhibisyonu aktiviteler IC50 (%50 inhibitör derişimi) değeri 1000 µM’dan yüksek derişimlerde iken, standart olan Galantamin bileşiğinde IC50 değeri 21.30 µM ve 37.03 µM’da gözlenmiştir. Antioksidan aktivite, standart olan gallik asit için IC50 68.83 µM iken, imidazol türevlerinde IC50 1000 µM’dan yüksek derişimlerde gözlenmiştir. Bileşiklerde aktivite gözlenmemesi, yan zincirdeki aromatik halkanın enzim etkileşiminde sterik engel oluşturduğunu düşündürmüştür. Aril (alkil) azol grubu bileşiklerde, yan zincirde alkil (doymuş, doymamış, halojenli sübstitüe vb) grubu taşıyan yeni türevler sentezlenerek bu aktivitelerin değerlendirilmesi planlanmaktadır.

28 February 2026 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
MDMefküre Durmuş
Mefküre Durmuş
AAAslınur Albayrak
Aslınur Albayrak
SKSena Güzel Karahan
Sena Güzel Karahan
The role of pharmacists in delivering counseling and care services for patients with HIV/AIDS is becoming increasingly significant. The knowledge and attit